

Skin Pathway Group – Etoposide Oral in Mycosis Fungoides

Indication:	Palliative therapy for Mycosis Fungoides, stage IIb-IVb Patients able to tolerate oral treatment		
	Etoposide is not licensed for this indication, and therefore use should be in line with individual Trust governance process		
Regimen details:	Etoposide	50mg Twice daily	Orally Days 1 to 7 Increase duration of therapy to 10 then 14 days, depending on toxicity
Administration:	Capsules to be swallowed whole on an empty stomach, half an hour before or 2 hours after a meal. Available as 50mg and 100mg capsules.		
Frequency:	21 day cycle Usually no more than 6 cycles		
Pre-medication:	Not applicable		
Anti- emetics:	Low emetogenicity Follow Local Anti-emetic Policy		
Supportive medication:	Not applicable		
Extravasation:	Not applicable		
Regular investigation:	Prior to Cycle 1:		
	FBC		Day 1 (within 14 days)
	LFTs		Day 1 (within 14 days)
	U&Es		Day 1 (within 14 days)

Version: 1.0 Supersedes: all other versions	Approved by LCA Skin Pathway Chemotherapy Lead: Mark Harries	
Reason for Update: LCA Protocol Development	Approved by LCA Joint Delivery Subgroup Co-Chairs: Pauline McCalla & Rebecca Johl	
Prepared by: Ravi Shaunak	Approved by LCA Medicines & Chemotherapy Steering Group Chair:	
Second check by: Sanna Eestila	Date prepared: January 2015	Review Date: : January 2017
<p>Disclaimer: The Joint Delivery Chemotherapy Nurse/Oncology Pharmacist Group is a sub-group of the Medicines & Chemotherapy Steering Group (MCSG) working within the London Cancer Alliance Integrated Cancer System (LCA). The output of the LCA MCSG includes documentation that can be adopted by healthcare organisations at their discretion. It is the responsibility of each individual organisation to ensure that appropriate governance and safety clearance procedures within their own clinical service have been followed prior to implementation of any such pieces of work. LCA assume no responsibility for this process within individual organisations, and no responsibility for the clinical management of individual patients or patient groups. Any clinical queries regarding individual patients or documentation should be directed to the relevant clinical team within the most appropriate healthcare organisation.</p> <p>©LCA Copyright 2014</p>		

Prior to Cycle 2 onwards:

FBC	Day 1 (within 72 hours)
LFTs	Day 1 (within 72 hours)
U&Es	Day 1 (within 72 hours)

Toxicities: Nausea and vomiting, myelosuppression- risk of sepsis and thrombocytopenia, alopecia, stomatitis
 Anaphylactic reactions have been reported following etoposide administration.
 Adequate contraceptive methods should be used during therapy.

DOSE MODIFICATIONS

Haematological Toxicity

Neutrophils (x 10 ⁹ /L)		Platelets (x 10 ⁹ /L)	Etoposide Dose
<1.0	or	< 100	Delay for 1 week, then reduce duration of therapy: from 7 days to 5 days or 10 days to 7 days or 14 days to 10 days

Non-haematological Toxicities

Renal Impairment

Creatinine Clearance (ml/min)	Etoposide Dose
> 50	100%
15 - 50	75%
< 15	50%

Hepatic Impairment

Bilirubin (micromol/L)		AST (units/L)	Etoposide Dose
26-51	or	60-180	50% dose
>51	or	>180	Clinical decision.

Location of regimen delivery: Etoposide to be supplied to the patient for oral self-administration

Drug interactions: Cyclosporin (high doses) increased etoposide plasma levels/ toxicity.
 Glucosamine- possible reduced etoposide effectiveness
 St John's wort- possible reduced etoposide effectiveness
 Monitor INR levels carefully if on concomitant warfarin
 Grapefruit juice- reduced etoposide plasma levels

References: www.medicines.org.uk

Version: 1.0 Supersedes: all other versions	Approved by LCA Skin Pathway Chemotherapy Lead: Mark Harries
Reason for Update: LCA Protocol Development	Approved by LCA Joint Delivery Subgroup Co-Chairs: Pauline McCalla & Rebecca Johl
Prepared by: Ravi Shaunak	Approved by LCA Medicines & Chemotherapy Steering Group Chair:
Second check by: Sanna Eestila	Date prepared: January 2015 Review Date: : January 2017
<p>Disclaimer: The Joint Delivery Chemotherapy Nurse/Oncology Pharmacist Group is a sub-group of the Medicines & Chemotherapy Steering Group (MCSG) working within the London Cancer Alliance Integrated Cancer System (LCA). The output of the LCA MCSG includes documentation that can be adopted by healthcare organisations at their discretion. It is the responsibility of each individual organisation to ensure that appropriate governance and safety clearance procedures within their own clinical service have been followed prior to implementation of any such pieces of work. LCA assume no responsibility for this process within individual organisations, and no responsibility for the clinical management of individual patients or patient groups. Any clinical queries regarding individual patients or documentation should be directed to the relevant clinical team within the most appropriate healthcare organisation.</p> <p>©LCA Copyright 2014</p>	

Chemotherapy Guidelines: Clinical Oncology (2001) 13: S2-11, RCR
 Joint British Association of Dermatologists and U.K.
 Cutaneous Lymphoma Group guidelines for the management of
 primary cutaneous T-cell lymphomas British Journal of Dermatology
 2003; 149: 1095–1107.

Version: 1.0 Supersedes: all other versions	Approved by LCA Skin Pathway Chemotherapy Lead: Mark Harries
Reason for Update: LCA Protocol Development	Approved by LCA Joint Delivery Subgroup Co-Chairs: Pauline McCalla & Rebecca Johl
Prepared by: Ravi Shaunak	Approved by LCA Medicines & Chemotherapy Steering Group Chair:
Second check by: Sanna Eestila	Date prepared: January 2015 Review Date: : January 2017
<p>Disclaimer: The Joint Delivery Chemotherapy Nurse/Oncology Pharmacist Group is a sub-group of the Medicines & Chemotherapy Steering Group (MCSG) working within the London Cancer Alliance Integrated Cancer System (LCA). The output of the LCA MCSG includes documentation that can be adopted by healthcare organisations at their discretion. It is the responsibility of each individual organisation to ensure that appropriate governance and safety clearance procedures within their own clinical service have been followed prior to implementation of any such pieces of work. LCA assume no responsibility for this process within individual organisations, and no responsibility for the clinical management of individual patients or patient groups. Any clinical queries regarding individual patients or documentation should be directed to the relevant clinical team within the most appropriate healthcare organisation.</p> <p>©LCA Copyright 2014</p>	